MYD88 mutant lymphoplasmacytic lymphoma/Waldenström macroglobulinemia has distinct clinical and pathological features as compared to its mutation negative counterpart. Issue 2 (February 2015)

• Record Type: Journal Article
• Authors: Patkar, Nikhil; Subramanian, P. G.; Deshpande, Prashant; Ghodke, Kiran; Tembhare, Prashant; Mascarenhas, Russel; Muranjan, Aditi; Chaudhary, Shruti; Bagal, Bhausaheb; Gujral, Sumeet; Sengar, Manju; Menon, Hari
• Is Part Of: Leukemia & lymphoma. Volume 56:Issue 2(2015:Feb.)
• Page Start: 420
• Page End: 425
• Publication Date: 2015-02
• Subjects: Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.3109/10428194.2014.924123
• Languages: English
• ISSNs: 1042-8194

Abstract

<abstract> <title>Abstract</title> <p>In a first series from India, we report 32 cases of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia (LPL/WM) over 7 years. Here, we analyzed 32 patients with LPL/WM for <italic>MYD88</italic> L265P mutation and correlated mutation staus with hematological and biochemical parameters and also with the International Prognostic Scoring System (ISSWM) and treatment response. Twenty-seven out of 32 cases of LPL/WM (84.3%) harbored the <italic>MYD88</italic> L265P mutation. <italic>MYD88</italic> wild-type WM was associated with a lower number of tumor cells (<italic>p</italic> &lt; 0.01) and older age (<italic>p</italic> = 0.02) and a lower ISSWM score at presentation (<italic>p</italic> = 0.03) as compared to mutated LPL/WM. On evaluation of response (<italic>n</italic> = 23), 44.4% of patients with <italic>MYD88</italic> mutated LPL/WM had progressive disease, whereas no patient in the <italic>MYD88</italic> unmutated group changed their baseline status. We confirm the high frequency of <italic>MYD88</italic> mutations in LPL/WM. Although the number of <italic>MYD88</italic> wild-type cases was limited, our data indicate that <italic>MYD88</italic> may represent an adverse prognostic marker for LPL/WM.</p> </abstract>